Apple is bringing back a feature at the center of a big Apple Watch legal battle
The feature, which is meant to help people understand their respiratory health, will come to Apple Watch Series 9, Series 10 and Ultra 2 models in the US currently missing the functionality through a software update, Apple said in a statement Thursday. It marks the latest development in a years-long saga that saw Apple temporarily yank its popular smartwatches from US store shelves during the critical holiday season nearly two years ago.
In 2023, the International Trade Commission ruled that Apple had violated a patent from digital health company Masimo related to its pulse oximeter technology. Apple said at the time that it 'strongly disagrees with the order.'
When the order was issued, it applied only to new Apple Watches in the United States, meaning those who already owned an Apple Watch with the feature were unaffected. Apple Watches sold outside the United States were also unaffected by the order. Still, the Americas, which incudes the United States, is Apple's biggest market.
Apple has positioned the Apple Watch has being a potentially life-saving device, and the company is said to be exploring more ambitious health efforts like noninvasive glucose monitoring, according to Bloomberg.
Pulse oximeters shine light through the skin to calculate a wearer's blood oxygen saturation, similar to the finger-clip devices used in clinical settings. Apple introduced the feature on the Apple Watch Series 6 in 2020 in the early stretch of the pandemic.
While blood oxygen monitoring may not be a selling point for consumers, health features like these could be critical in helping Apple cement its position ahead of the competition as its rivals increasingly pour resources into digital health.
Samsung, Apple's chief rival in the consumer electronics space, is charging ahead on the digital health front by introducing features to its smartwatches meant to help users remain healthy as they age. And Google is widely expected to release a new version of its Pixel Watch next week.
The update coming on Thursday will bring a 'redesigned' version of the blood oxygen feature to US users who currently don't have access to it. Apple Watch owners will have to update to software version watchOS 11.6.1 and pair their device with an iPhone running on iOS 18.6.1.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections. The company recently secured additional Medicare reimbursement for its aprevo personalized interbody implants for cervical fusion procedures, effective October 1, enhancing its financial outlook. This favorable reimbursement, granted through the Centers for Medicare & Medicaid Services' (CMS) New Technology Add-On Payment (NTAP) program in the Hospital Inpatient Prospective Payment Systems (IPPS) Final Rule for fiscal year 2026, means cervical fusion procedures using aprevo devices will be eligible for an additional $21,125 beyond standard Medicare Severity-Diagnosis-Related Groups (MS-DRGs) for qualifying inpatient benefit extends to private payors as well, utilizing unique ICD-10-PCS procedure codes. Carlsmed, which priced its initial public offering of 6.7 million shares at $15 per share in July, focuses on AI-enabled personalized spine surgery solutions. Its aprevo cervical system, having received FDA Breakthrough Device designation, is anticipated for a U.S. commercial launch in of America Securities (BofA) has initiated coverage on Carlsmed with a Buy rating and a price forecast of $16, recognizing the company's potential to establish a new standard of care in spine fusion. BofA analyst Travis Steed highlighted Carlsmed's differentiated technology and robust outlook, assigning a premium valuation of 5x 2026 estimated revenue. This premium, higher than recent medtech IPOs and other spine companies, is justified by Carlsmed's projected high revenue growth and strong gross margin profile. BofA conservatively forecasts Carlsmed will add around 20-25 new surgeons each quarter through 2027, indicating a steady increase in adoption. Carlsmed forecasts impressive top-line growth: 66% in 2025 and an annual 40-45% through 2028. Its asset-light business model is expected to support profitability, with gross margins in the mid-70s and capital expenditures at just 1% of sales, significantly lower than the approximately 10% for traditional spine peers. BofA estimates the total spine market at roughly $1.4 billion, with a compound annual growth rate (CAGR) of approximately 1.5%. In the first quarter of 2025, the global spine market (including biologics) saw 2.6% organic growth, driven by a 4.1% increase in the U.S. market. Despite the market being largely commoditized and dominated by major players like Medtronic Plc (NYSE:MDT), Globus Medical Inc (NYSE:GMED), Alphatec Holdings Inc. (NASDAQ:ATEC), Johnson and Johnson (NYSE:JNJ), and Orthofix Medical Inc. (NYSE:OFIX) (who collectively hold about 70% of the market), spine surgeons notably favor new technology. The remaining 30% of the market is split among many smaller companies, creating an opportunity for new market entrants with disruptive technology like Carlsmed's to gain traction. BofA sees significant market share capture potential for Carlsmed, with analyst Steed estimating total revenue of $133 million in 2028, representing only about 1% of the total U.S. spine market. Price Action: CARL stock is trading higher by 0.88% to $13.70 at last check Monday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Measles outbreak ends in West Texas, health officials say
(Reuters) -The measles outbreak in West Texas has ended, state health officials said on Monday, after meeting the criteria of six weeks since the last reported case. Texas is now shifting focus to vaccination campaigns to strengthen immunity and prevent future outbreaks, the Department of State Health Services (DSHS) said. The outbreak, which began in late January, led to 762 confirmed cases as of August 18, with 99 hospitalizations and two fatalities in school-aged children, according to the state's health department. Texas led a surge in cases nationally, with the United States recording its largest outbreak since the disease was declared eliminated in the United States in 2000. While the Texas DSHS will continue to monitor the cases, it has decided to discontinue its interactive outbreak dashboard. "The end of this outbreak does not mean the threat of measles is over. Since there are ongoing outbreaks of measles in North America and around the world, it is likely that there will be additional cases of measles this year in Texas," the DSHS said. Measles is a highly contagious viral infection that causes symptoms such as fever, cough and a characteristic rash. It can also lead to severe complications like pneumonia and encephalitis. The Centers for Disease Control and Prevention has reported 1,356 confirmed measles cases nationally as of August 5, but the updates have been delayed following the August 8 shooting on its Atlanta headquarters, the CDC said. "We remain in close communication with public health partners and jurisdictions reporting measles and will resume regular data updates as soon as possible," a CDC spokesperson said. Solve the daily Crossword
Yahoo
27 minutes ago
- Yahoo
Mortgage Advisor: Should You Get Your Mortgage Through These Untraditional Companies?
About 7.79% of all U.S. mortgages now originated through fintech platforms, according to a study published in the Journal of Monetary Economics. Instead of a traditional bank or credit union, companies like are helping homeowners finance their homes. This doesn't include nonbank direct lenders like Rocket Mortgage, which make up around 38%. For You: Read Next: Just because people are using these nonbank lenders, doesn't mean it's the right move for you. Sure, applying with one of these companies online may offer convenience and a faster application process. But are these lenders all that different from banks? What Are Fintech Lenders? At its core, these lenders are companies that use technology like a website or an app to help homebuyers apply for and manage their loans online. They market themselves as more convenient than traditional banks. Behind the scenes though, they're basically doing the same work. 'From an operational point of view, there is really no difference between fintech and brick and mortar lenders,' said Casey Fleming, advisor at Silicon Valley Mortgage and author of 'The Loan Guide.' 'All of them need to process, underwrite, fund and sell the mortgages they originate.' Once these direct lenders fund the loan, they typically sell them on the secondary market to agencies like Fannie Mae or Freddie Mac or investors. Discover Next: What's the Difference Between Fintech Lenders and Banks? The truth is that there isn't much difference between the two when it comes to the lending process. Traditional banks and fintech companies also pull funding from the same sources. The difference lies more in how you interact with these companies. 'They are only different from each other in terms of how consumers perceive them,' Fleming explained. Essentially, you can complete all tasks from the preapproval process to signing closing documents online. With traditional banks and credit unions, you may have other ways you need to communicate with the lender, like in person or phone. Fleming added that it may also be about how people feel about the experience they have with their lender. 'Homebuyers usually don't want to talk to a salesperson,' he explained. 'The online shopping experience allows them to shop with many lenders without being pressured, spend as much time as they want doing so and makes them feel as though they have found the best deal.' Is There a Catch? Sure, it sounds like fintech or online nonbank companies have more advantages over banks, but that's not always the case. For one, they may not always have the best rates, even if it's more convenient to compare lenders and apply for a loan. Plus, some may not have the best customer service or personalized assistance understanding your loan options. Traditional banks may still have an edge. Some may offer perks if you have a longstanding relationship with them, like waiving certain fees. Or if you prefer to speak to someone in person to walk you through the process, you may be better off heading to your local branch. The ultimate goal is to understand your priorities and do your research to find the best rates and terms, not necessarily the best loan platform. 'Different programs were designed for different circumstances, goals and concerns,' Fleming said. 'The happiest homeowners are the ones who make a well-informed decision and choose the option that best suits their family's needs.' More From GOBankingRates 5 Old Navy Items Retirees Need To Buy Ahead of Fall 10 Used Cars That Will Last Longer Than the Average New Vehicle This article originally appeared on Mortgage Advisor: Should You Get Your Mortgage Through These Untraditional Companies?
